bis(3--5-)-cyclic-diguanylic-acid and Pneumococcal-Infections

bis(3--5-)-cyclic-diguanylic-acid has been researched along with Pneumococcal-Infections* in 2 studies

Other Studies

2 other study(ies) available for bis(3--5-)-cyclic-diguanylic-acid and Pneumococcal-Infections

ArticleYear
3',5'-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection.
    Biochemical and biophysical research communications, 2009, Sep-25, Volume: 387, Issue:3

    3',5'-Cyclic diguanylic acid (cdiGMP) is emerging as a universal bacterial second messenger in regulating bacterial growth on surfaces. It has been recently shown that cdiGMP stimulates innate immunity and enhances antigen-specific humoral and cellular immune responses. We herein report that intranasal (i.n.) administration with cdiGMP induces an acute but transient inflammatory response and activation of dendritic cells in the lungs. Moreover, i.n. immunization of mice with pneumococcal surface adhesion A (PsaA) in conjunction with cdiGMP elicited strong antigen-specific serum immunoglobulin G (IgG) and secretory IgA antibody responses at multiple mucosal surfaces. More importantly, the immunized mice showed significantly reduced nasopharyngeal Streptococcus pneumoniae colonization. These results, for the first time, provide direct evidence for the induction of protection against mucosal bacterial infections by cdiGMP as an adjuvant.

    Topics: Administration, Intranasal; Animals; Cyclic GMP; Cytokines; Dendritic Cells; Female; Immunity, Mucosal; Immunoglobulin A; Immunoglobulin G; Lung; Mice; Mice, Inbred BALB C; Pneumococcal Infections; Streptococcus pneumoniae

2009
c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection.
    Vaccine, 2008, Aug-26, Volume: 26, Issue:36

    Cyclic diguanylate (c-di-GMP) is a unique bacterial intracellular signaling molecule capable of stimulating enhanced protective innate immunity against various bacterial infections. The effects of intranasal pretreatment with c-di-GMP, or intraperitoneal coadministration of c-di-GMP with the pneumolysin toxoid (PdB) or pneumococcal surface protein A (PspA) before pneumococcal challenge, were investigated in mice. We found that c-di-GMP had no significant direct short-term effect on the growth rate of Streptococcus pneumoniae either in vitro or in vivo. However, intranasal pretreatment of mice with c-di-GMP resulted in a significant decrease in bacterial load in lungs and blood after serotypes 2 and 3 challenge, and a significant decrease in lung titers after serotype 4 challenge. Potential cellular mediators of these enhanced protective responses were identified in lungs and draining lymph nodes. Intraperitoneal coadministration of c-di-GMP with PdB or PspA before challenge resulted in significantly higher antigen-specific antibody titers and increased survival of mice, compared to that obtained with alum adjuvant. These findings demonstrate that local or systemic c-di-GMP administration stimulates innate and adaptive immunity against invasive pneumococcal disease. We propose that c-di-GMP can be used as an effective broad spectrum immunomodulator and vaccine adjuvant to prevent infectious diseases.

    Topics: Adjuvants, Immunologic; Administration, Intranasal; Alum Compounds; Animals; Antibodies, Bacterial; Bacterial Proteins; Blood; Colony Count, Microbial; Cyclic GMP; Female; Immunologic Factors; Injections, Intraperitoneal; Lung; Lymph Nodes; Male; Mice; Mice, Inbred BALB C; Pneumococcal Infections; Pneumococcal Vaccines; Streptococcus pneumoniae; Streptolysins; Survival Analysis

2008